Literature DB >> 27664858

Old chemotherapy makes a comeback: dual alkylator therapy for pediatric high-grade glioma.

Eric Bouffet1, Vijay Ramaswamy2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27664858      PMCID: PMC5035534          DOI: 10.1093/neuonc/now200

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  12 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

2.  Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Authors:  Sameer Agnihotri; Aaron S Gajadhar; Christian Ternamian; Thierry Gorlia; Kristin L Diefes; Paul S Mischel; Joanna Kelly; Gail McGown; Mary Thorncroft; Brett L Carlson; Jann N Sarkaria; Geoffrey P Margison; Kenneth Aldape; Cynthia Hawkins; Monika Hegi; Abhijit Guha
Journal:  J Clin Invest       Date:  2011-12-12       Impact factor: 14.808

3.  Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

Authors:  Ulrich Herrlinger; Johannes Rieger; Dorothee Koch; Simon Loeser; Britta Blaschke; Rolf-Dieter Kortmann; Joachim P Steinbach; Thomas Hundsberger; Wolfgang Wick; Richard Meyermann; Ta-Chih Tan; Clemens Sommer; Michael Bamberg; Guido Reifenberger; Michael Weller
Journal:  J Clin Oncol       Date:  2006-09-20       Impact factor: 44.544

4.  Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.

Authors:  Kenneth J Cohen; Ian F Pollack; Tianni Zhou; Allen Buxton; Emiko J Holmes; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Ronald L Hamilton; Robert S Lavey; Richard L Heideman
Journal:  Neuro Oncol       Date:  2011-03       Impact factor: 12.300

5.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

6.  Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  J Plowman; W R Waud; A D Koutsoukos; L V Rubinstein; T D Moore; M R Grever
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

7.  Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.

Authors:  Martin Glas; Caroline Happold; Johannes Rieger; Dorothee Wiewrodt; Oliver Bähr; Joachim P Steinbach; Wolfgang Wick; Rolf-Dieter Kortmann; Guido Reifenberger; Michael Weller; Ulrich Herrlinger
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

8.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

9.  Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.

Authors:  J L Finlay; J M Boyett; A J Yates; J H Wisoff; J M Milstein; J R Geyer; S J Bertolone; P McGuire; J M Cherlow; M Tefft
Journal:  J Clin Oncol       Date:  1995-01       Impact factor: 44.544

Review 10.  Pediatric high-grade glioma: biologically and clinically in need of new thinking.

Authors:  Chris Jones; Matthias A Karajannis; David T W Jones; Mark W Kieran; Michelle Monje; Suzanne J Baker; Oren J Becher; Yoon-Jae Cho; Nalin Gupta; Cynthia Hawkins; Darren Hargrave; Daphne A Haas-Kogan; Nada Jabado; Xiao-Nan Li; Sabine Mueller; Theo Nicolaides; Roger J Packer; Anders I Persson; Joanna J Phillips; Erin F Simonds; James M Stafford; Yujie Tang; Stefan M Pfister; William A Weiss
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more
  3 in total

Review 1.  Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.

Authors:  Magimairajan Issai Vanan; D Alan Underhill; David D Eisenstat
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

2.  Effects of different molecular subtypes and tumor biology on the prognosis of medulloblastoma.

Authors:  Yavuz Aras; Duygu Dölen; Ayca İribas Çelik; Gozde Kılıç; Rejin Kebudi; Gökçen Ünverengil; Pulat Akın Sabancı; Ali Nail İzgi
Journal:  Childs Nerv Syst       Date:  2021-09-22       Impact factor: 1.475

3.  MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating β-catenin and causing activation of FOXO3a.

Authors:  Ming Lu; Yong Wang; Shizhen Zhou; Jun Xu; Jing Li; Rongjie Tao; Yufang Zhu
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.